[1]
|
中国医师协会肾脏内科医师分会肾性贫血指南工作组. 中国肾性贫血诊治临床实践指南[J]. 中华医学杂志, 2021, 101(20): 1463-1502.
|
[2]
|
Ma, J., Dou, Y., Zhang, H., et al. (2017) Correlation between Inflammatory Biomarkers and Red Blood Cell Life Span in Chronic Hemodialysis Patients. Blood Purification, 43, 200-205. https://doi.org/10.1159/000452728
|
[3]
|
Li, P.K.T., Choy, A.S.M., Bavanandan, S., et al. (2021) Anemia Manage-ment in Peritoneal Dialysis: Perspectives from the Asia Pacific Region. Kidney Medicine, 3, 405-411. https://doi.org/10.1016/j.xkme.2021.01.011
|
[4]
|
van Haalen, H., Jackson, J., Spinowitz, B., Milligan, G. and Moon, R. (2020) Impact of Chronic Kidney Disease and Anemia on Health-Related Quality of Life and Work Productiv-ity: Analysis of Multinational Real-World Data. BMC Nephrology, 21, Article No. 88. https://doi.org/10.1186/s12882-020-01746-4
|
[5]
|
Perlman, R.L., Zhao, J., Fuller, D.S., et al. (2019) International Anemia Prevalence and Management in Peritoneal Dialysis Patients. Peritoneal Dialysis International, 39, 539-546. https://doi.org/10.3747/pdi.2018.00249
|
[6]
|
齐慧, 周弋, 王丹, 等. 上海市浦东新区成人慢性肾脏病流行现状及与贫血的相关性[J]. 上海预防医学, 2011, 23(11): 529-531, 535.
|
[7]
|
Zhou, Q.G., Jiang, J.P., Wu, S.J., et al. (2012) Current Pattern of Chinese Dialysis Units: A Cohort Study in a Representative Sample of Units. Chinese Medical Journal, 125, 3434-3439.
|
[8]
|
Haase, V.H. (2021) Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitors in the Treatment of Anemia of Chronic Kidney Disease. Kidney International Supplements (2011), 11, 8-25. https://doi.org/10.1016/j.kisu.2020.12.002
|
[9]
|
Mima, A. (2021) Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitors for Renal Anemia in Chronic Kidney Disease: Advantages and Disadvantages. European Journal of Pharma-cology, 912, Article ID: 174583.
https://doi.org/10.1016/j.ejphar.2021.174583
|
[10]
|
González, F. (1998) Effects of Normal as Compared with Low Hematocrit Values in Patients with Cardiac Disease Undergoing Hemodialysis and Receiving Epoetin. The New England Journal of Medicine, 339, 2023-2024.
https://doi.org/10.1056/NEJM199812313392713
|
[11]
|
Wish, J.B. (2021) Treatment of Anemia in Kidney Disease: Beyond Erythropoietin. Kidney International Reports, 6, 2540-2553. https://doi.org/10.1016/j.ekir.2021.05.028
|
[12]
|
Mitsopoulos, E., Lysitska, A., Pateinakis, P., et al. (2020) Efficacy and Safety of a Low Monthly Dose of Intravenous Iron Sucrose in Peritoneal Dialysis Patients. International Urology and Nephrology, 52, 387-392.
https://doi.org/10.1007/s11255-019-02362-4
|
[13]
|
Pandey, R., Daloul, R. and Coyne, D.W. (2016) Iron Treatment Strategies in Dialysis-Dependent CKD. Seminars in Nephrology, 36, 105-111. https://doi.org/10.1016/j.semnephrol.2016.02.004
|
[14]
|
Gutiérrez, O.M. (2021) Treatment of Iron Deficiency Ane-mia in CKD and End-Stage Kidney Disease. Kidney International Reports, 6, 2261-2269. https://doi.org/10.1016/j.ekir.2021.05.020
|
[15]
|
Cirillo, L., Somma, C., Allinovi, M., et al. (2021) Ferric Carboxy-maltose vs. Ferrous Sulfate for the Treatment of Anemia in Advanced Chronic Kidney Disease: An Observational Retro-spective Study and Cost Analysis. Scientific Reports, 11, Article No. 7463. https://doi.org/10.1038/s41598-021-86769-z
|
[16]
|
Onken, J.E., Bregman, D.B., Harrington, R.A., et al. (2014) Fer-ric Carboxymaltose in Patients with Iron-Deficiency Anemia and Impaired Renal Function: The REPAIR-IDA Trial. Nephrology Dialysis Transplantation, 29, 833-842.
https://doi.org/10.1093/ndt/gft251
|
[17]
|
Hussain, U., Zia, K., Iqbal, R., Saeed, M. and Ashraf, N. (2019) Efficacy of a Novel Food Supplement (Ferfer®) Containing Microencapsulated Iron in Liposomal Form in Female Iron Deficiency Anemia. Cureus, 11, e4603.
https://doi.org/10.7759/cureus.4603
|
[18]
|
Pisani, A., Riccio, E., Sabbatini, M., Andreucci, M., Del Rio, A. and Vis-ciano, B. (2015) Effect of Oral Liposomal Iron versus Intravenous Iron for Treatment of Iron Deficiency Anaemia in CKD Patients: A Randomized Trial. Nephrology Dialysis Transplantation, 30, 645-652. https://doi.org/10.1093/ndt/gfu357
|
[19]
|
Floege, J., Funk, F., Ketteler, M., et al. (2020) Iron Kinetics Following Treatment with Sucroferric Oxyhydroxide or Ferric Citrate in Healthy Rats and Models of Anaemia, Iron Overload or In-flammation. Nephrology Dialysis Transplantation, 35, 946-954. https://doi.org/10.1093/ndt/gfaa030
|
[20]
|
Lewis, J.B., Sika, M., Koury, M.J., et al. (2015) Ferric Citrate Controls Phosphorus and Delivers Iron in Patients on Dialysis. Journal of the American Society of Nephrology, 26, 493-503. https://doi.org/10.1681/ASN.2014020212
|
[21]
|
Umanath, K., Jalal, D.I., Greco, B.A., Umeukeje, E.M., et al. (2015) Ferric Citrate Reduces Intravenous Iron and Erythropoiesis-Stimulating Agent Use in ESRD. Journal of the American Society of Nephrology, 26, 2578-2587.
https://doi.org/10.1681/ASN.2014080842
|
[22]
|
Block, G., Fishbane, S., Rodriguez, M., et al. (2014) A 12-Week, Double-Blind, Placebo-Controlled Trial of Ferric Citrate for the Treatment of Iron Deficiency Anemia and Reduction of Serum Phosphate in Patients with CKD Stages 3-5. American Journal of Kidney Diseases, 65, 728-736. https://doi.org/10.1053/j.ajkd.2014.10.014
|
[23]
|
Phan, O., Maillard, M., Peregaux, C., et al. (2013) PA21, a New Iron-Based Non Calcium Phosphate Binder, Prevents Vascular Calcification in Chronic Renal Failure Rats. Journal of Pharmacology and Experimental Therapeutics, 346, 281-289. https://doi.org/10.1124/jpet.113.204792
|
[24]
|
Iida, A., Kemmochi, Y., Kakimoto, K., et al. (2013) Ferric Citrate Hydrate, a New Phosphate Binder, Prevents the Complica-tions of Secondary Hyper Parathyroidism and Vascular Calcification. American Journal of Nephrology, 37, 346-358.
https://doi.org/10.1159/000348805
|
[25]
|
Gupta, A., Lin, V., Guss, C., Pratt, R., et al. (2015) Ferric Pyrophosphate Citrate Adminis Tered via Dialysate Reduces Erythropoiesis-Stimulating Agent Use and Maintains Hemoglobin in He-modialysis Patients. Kidney International, 88, 1187-1194. https://doi.org/10.1038/ki.2015.203
|
[26]
|
Atkinson, M.A., Kim, J.Y., Roy, C.N., Warady, B.A., White, C.T. and Furth, S.L. (2015) Hepcidin and Risk of Anemia in CKD: A Cross-Sectional and Longitudinal Analysis in the CKiD Cohort. Pediatric Nephrology, 30, 635-643.
https://doi.org/10.1007/s00467-014-2991-4
|
[27]
|
Van Eijk, L.T., John, A.S., Schwoebel, F., et al. (2014) Effect of the Antihepcidin Spiegelmer Lexaptepid on Inflammation-Induced Decrease in Serumiron in Humans. Blood, 124, 2643-2646.
https://doi.org/10.1182/blood-2014-03-559484
|
[28]
|
Eschbach, J.W., Abdulhadi, M.H., Browne, J.K., et al. (1989) Recombinant Human Erythropoietin in Anemic Patients with End-Stage Renal Disease. Results of a Phase III Multicenter Clinical Trial. Annals of Internal Medicine, 111, 992-1000. https://doi.org/10.7326/0003-4819-111-12-992
|
[29]
|
Bello, A.K., Ribic, C.M., Cournoyer, S.H., et al. (2018) Transfusion Management of Incident Dialysis Patients in Canada: A Prospective Observational Study. Canadian Journal of Kidney Health and Disease, 5.
https://doi.org/10.1177/2054358118778564
|
[30]
|
St Peter, W.L., Guo, H., Kabadi, S., et al. (2018) Prevalence, Treatment Patterns, and Healthcare Resource Utilization in Medicare and Commercially Insured Non-Dialysis-Dependent Chronic Kidney Disease Patients with and without Anemia in the United States. BMC Nephrology, 19, Article No. 67. https://doi.org/10.1186/s12882-018-0861-1
|
[31]
|
Lopes, M.B., Tu, C., Zee, J., Guedes, M., et al. (2021) A Re-al-World Longitudinal Study of Anemia Management in Non-Dialysis-Dependent Chronic Kidney Disease Patients: A Multinational Analysis of CKD Opps. Scientific Reports, 11, Article No. 1784. https://doi.org/10.1038/s41598-020-79254-6
|
[32]
|
苏超, 卞显倩, 王刚, 张蕖, 杜婷婷, 何衡杰. 生血宁与多糖铁治疗血液透析患者肾性贫血的疗效比较[J]. 临床肾脏病杂志, 2020, 20(4): 293-296, 321.
|
[33]
|
Casu, C., Pet-tinato, M., Liu, A., et al. (2020) Correcting β-Thalassemia by Combined Therapies that Restrict Iron and Modulate Erythropoietin Activity. Blood, 136, 1968-1979. https://doi.org/10.1182/blood.2019004719
|
[34]
|
檀金川, 于晓辉. 滋肾生血方治疗长期血液透析患者肾性贫血的临床观察[J]. 北京中医药, 2013(8): 573-576.
|
[35]
|
金伟民, 包晓星. 中西医结合治疗肾性贫血疗效观察[J]. 现代中西医结合杂志, 2004, 13(6): 769-769.
|
[36]
|
沈元丽, 王莹. 腹膜透析治疗慢性肾功能衰竭16例分析[J]. 慢性病学杂志, 2010, 12(8): 906-907.
|